BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C. Wainwright, raised the price target for BridgeBio Pharma, Inc. (NASDAQ:BBIO) from $53 to $56 and kept the stock’s buy rating.

BridgeBio price target raised to $56 from $53 at H.C. Wainwright

A team of scientists in white lab coats reviewing lab results in a research facility.

Positive momentum for the company is proven by the fast uptake of the Attruby product, which is the driving force behind this bullish forecast.

For adult patients with ATTR-CM, Attruby is the only nearly full (≥90%) stabilizer of Transthyretin (TTR) that has been approved in the United States to lower cardiovascular mortality and hospitalizations linked to cardiovascular disease. In general, Attruby was highly received. Abdominal pain and diarrhea were the most frequent, moderate side effects that went away without stopping the medication. BridgeBio Pharma, Inc. (NASDAQ:BBIO) provides a wide range of initiatives to facilitate patients’ access to our medications.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a novel biopharmaceutical business that was established to find, develop, test, and distribute revolutionary medications to treat people with hereditary disorders. The development programs in its pipeline span from early science to advanced clinical trials. BBIO is among the stocks with the biggest upside.

While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.